5-Amino-1MQ: Side Effects

Important Safety Notice#

No Human Safety Data Exists -- 5-Amino-1MQ has never been tested in humans in any formal clinical trial. Every statement about safety below is either extrapolated from animal studies or represents theoretical concerns based on the compound's mechanism. The actual side effect profile in humans is completely unknown.

This lack of human data stands in stark contrast to the compound's widespread commercial availability. Consumers should understand that using 5-Amino-1MQ means accepting entirely unknown risks.

Reported Side Effects#

Animal Study Observations#

In published preclinical studies, the following safety observations were made:

Neelakantan et al. 2018 (PMID: 29155147):

• No observable adverse effects in treated mice over 11 days
• No significant impact on food intake
• No behavioral abnormalities noted
• Body weight reduction attributed to fat loss, not general wasting

Dimet-Wiley et al. 2024 (PMID: 38969654):

• Aged mice tolerated NNMTi treatment without reported adverse effects
• No apparent toxicity in combination with exercise

Limitations of Animal Safety Data#

The apparent safety in mouse studies should not be interpreted as evidence of human safety:

• Treatment durations were short (11 days in the obesity study)
• Mice were monitored for gross adverse effects only, not subtle metabolic or organ-specific toxicity
• No formal toxicology studies (single-dose, repeat-dose, reproductive, carcinogenicity) have been published
• Mouse metabolism differs substantially from human metabolism
• Subcutaneous injection route in studies differs from oral route in commercial products

Theoretical Safety Concerns#

Based on the biological role of NNMT, several theoretical concerns warrant consideration:

Methylation Balance#

NNMT consumes SAM (S-adenosylmethionine) as a methyl donor. Inhibiting NNMT would increase SAM availability, potentially altering the methylation landscape across multiple pathways including DNA methylation, histone methylation, and other methyltransferase reactions. Long-term consequences of this shift are unknown.

Cancer Considerations#

NNMT has been found to be overexpressed in several cancer types, where it may play tumor-promoting roles. However, in other contexts, NNMT activity may serve protective functions. One published study showed 5-Amino-1MQ has anti-proliferative activity in HeLa cells (PMID: 33645410), but the net effect of NNMT inhibition on cancer risk over long-term use is unknown.

Metabolic Perturbation#

While increased NAD+ is generally considered beneficial, the broader metabolic consequences of NNMT inhibition -- including effects on polyamine metabolism, one-carbon metabolism, and other SAM-dependent pathways -- have not been systematically evaluated.

Contraindications#

No formal contraindications have been established due to the absence of human studies. Theoretical concerns include:

• Active cancer: Given the complex role of NNMT in various cancers, individuals with active malignancies should avoid NNMT inhibitors until the effects are better understood
• Pregnancy and lactation: No reproductive or developmental toxicity data exists
• Liver or kidney disease: Organ-specific effects of NNMT inhibition have not been evaluated

Drug Interactions#

No drug interaction studies have been conducted for 5-Amino-1MQ. Theoretical interactions include:

• SAM/SAMe supplements: NNMT inhibition preserves SAM; additional SAM supplementation could amplify methylation effects
• NAD+ precursors (NMN, NR): Combined effect on NAD+ levels is unstudied and could potentially cause excessive NAD+ elevation
• Medications metabolized by methyltransferases: NNMT inhibition could theoretically affect the metabolism of drugs processed by methylation pathways
• Anti-diabetic medications: Given the metabolic effects observed in animal models, potential interactions with glucose-lowering drugs should be considered